Lenvatinib as first treatment for liver cancer with moderate liver problems
Treatments studied
Part of Cancer clinical trials.
This trial tests lenvatinib, a targeted therapy, as the first treatment for people with hepatocellular carcinoma (HCC, a type of liver cancer) who have moderate liver damage (Child-Pugh B7-B8) and cannot have surgery or other local treatments. The goal is to see if it helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have been diagnosed with hepatocellular carcinoma (HCC, a type of liver cancer) that cannot be treated with surgery or other local therapies.
- You have at least one tumor that can be measured on a scan.
- Your liver function is moderately reduced (Child-Pugh class B7-B8).
- You have not had any systemic cancer treatment (like pills or infusions) for your liver cancer before.
- Your blood counts and organ function are within study limits.
- You are willing to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of the drug lenvatinib, a liver treatment called TACE, and the immunotherapy drug camrelizumab can shrink advanced hepatocellular carcinoma enough to make surgery (or “conversion resection”) possible. It may help some people live longer by improving the chance that the cancer can be removed.
This trial tests if removing the main liver tumor with surgery, followed by targeted therapy and immunotherapy, can help people with advanced liver cancer that has spread a little. It is for those who have not had prior treatment and whose liver is still working well.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This Phase 2 study tests lenvatinib plus an immunotherapy drug (tislelizumab) in people with advanced liver cancer that cannot be removed by surgery and who have hepatitis B infection. The goal is to see if this combination can shrink tumors and slow the cancer down, and to study helpful blood/biomarker signals.
This trial tests whether giving pembrolizumab (an immune therapy) and lenvatinib (a targeted pill) before planned liver surgery can improve outcomes for people with certain types of operable hepatocellular carcinoma (HCC). It’s meant for tumors that can be removed with curative intent, but still carry a risk of coming back.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.